Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Figure 12: Comparison of Efficacy

Treatment Types Newly diagnosed/previously untreated multiple myeloma Advanced/refractory/resistant multiple myeloma
VBCMP
Median survival 29 months24-25 17 months33
PPR 50% 72% 13%
VAD
Median survival 36-44 months30-31 10-17 months31, 33
PPR 50% 61-86% 22-70%
Thalidomide only
Median survival Estimated 2-year overall survival=96%42 Median overall survival not stated Estimated 2-year overall survival=48% ± 6%43 Median overall survival=5-58 months46,51,53,55,58,60
Complete response 16-25% 2-9%
PPR 25% 66-81% 34-100%
PPR 50% 34-38%a 8-43%a
Thalidomide plus dexamethasone
Median survival Median overall survival=30 months66 Estimated 2-year overall survival=55%76 Median OS=7-38 mo64,69-70,135
Complete response 8-16% 0-13%
PPR 25% 54-92% 54-75%
PPR 50% 17-64%a 22-55%a

aReports of PPR >50% can be misleading.

Return to Document

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care